Overall pooled prevalence of serum/plasma anti-NR2A/B antibodies was higher in SLE patients [24.6% (95% CI 18.5–32.0%)] compared to other autoimmune diseases [14.8% (95% CI 2.2-56.9)] and healthy controls [7.6% (95% CI 4.6–12.4%)] (p = 0.001) (40). Here, GRIN2A is linked to autoimmune disease.